Please ensure Javascript is enabled for purposes of website accessibility

AbbVie's Acquisition of Allergan Gets Help From Nestle and AstraZeneca

By Cory Renauer - Jan 27, 2020 at 11:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A pair of deals will remove some regulatory impediments to the merger.

Some unlikely good Samaritans are going out of their way to help AbbVie (ABBV 0.42%) and Allergan (AGN) complete the $63 billion merger deal the giant drugmakers announced last June. To appease antitrust regulators, AstraZeneca (AZN -0.18%) will take back control of an experimental psoriasis drug, and Nestle will acquire a gastrointestinal medication from Allergan.   

Hello again 

Allergan was developing a monoclonal antibody that inhibits interleukin 23 (IL-23) called brazikumab for the treatment of Crohn's disease and ulcerative colitis. AbbVie recently launched its own IL-23 inhibitor, risankizumab, under the brand name Skyrizi for the treatment of psoriasis.

A hand stuffing money in a doctor's pocket.

Image source: Getty Images.

Allergan had licensed brazikumab from AstraZeneca; now, it will return the antibody to the big British pharmaceutical company. At the moment, brazikumab and Skyrizi are both in late-stage clinical trials for the treatment of Crohn's disease and ulcerative colitis.

More than just cocoa 

You're probably more familiar with the Swiss food conglomerate's packaged food brands, but Nestle is also a leading player in the growing medical nutrition space.

Nestle will acquire Zenpep from Allergan for an undisclosed sum, adding it to its growing line of nutritional therapies designed for specific medical conditions. Zenprep is a collection of pancreatic enzymes that is especially useful for cystic fibrosis (CF) patients. Since Nestle already markets nutritional therapies for CF and a wide range of other disorders, Zenprep should fit comfortably in its portfolio.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Allergan plc Stock Quote
Allergan plc
AGN
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$153.80 (0.42%) $0.64
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$65.95 (-0.18%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.